Affimed (NASDAQ:AFMD) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Affimed (NASDAQ:AFMD – Get Rating) have earned a consensus recommendation of “Moderate Buy” from the eight analysts that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $5.67.

A number of research analysts recently commented on the stock. HC Wainwright reiterated a “buy” rating and set a $6.00 price objective on shares of Affimed in a research note on Friday, March 24th. Wells Fargo & Company reiterated an “overweight” rating and set a $7.00 price objective on shares of Affimed in a research note on Monday, March 27th. Stifel Nicolaus decreased their price target on shares of Affimed from $2.00 to $1.00 and set a “hold” rating on the stock in a research report on Friday, March 24th. Finally, StockNews.com initiated coverage on shares of Affimed in a research report on Thursday. They issued a “sell” rating on the stock.

Hedge Funds Weigh In On Affimed

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD boosted its stake in shares of Affimed by 30.9% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 13,570 shares of the biopharmaceutical company’s stock valued at $38,000 after buying an additional 3,202 shares during the period. Vanguard Group Inc. boosted its stake in shares of Affimed by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 1,386,701 shares of the biopharmaceutical company’s stock valued at $6,060,000 after buying an additional 5,499 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Affimed by 1.9% during the 1st quarter. Bank of New York Mellon Corp now owns 302,737 shares of the biopharmaceutical company’s stock valued at $1,323,000 after buying an additional 5,513 shares during the period. Advisor Group Holdings Inc. lifted its stake in shares of Affimed by 258.3% in the 1st quarter. Advisor Group Holdings Inc. now owns 8,967 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 6,464 shares during the last quarter. Finally, Virtu Financial LLC lifted its stake in shares of Affimed by 27.9% in the 2nd quarter. Virtu Financial LLC now owns 29,836 shares of the biopharmaceutical company’s stock valued at $83,000 after purchasing an additional 6,509 shares during the last quarter. Institutional investors and hedge funds own 61.73% of the company’s stock.

Affimed Stock Up 11.6 %

Shares of NASDAQ:AFMD opened at $1.08 on Monday. The company’s fifty day moving average is $0.81 and its two-hundred day moving average is $1.19. The stock has a market capitalization of $161.29 million, a price-to-earnings ratio of -1.71 and a beta of 2.53. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.64 and a current ratio of 5.66. Affimed has a 1-year low of $0.55 and a 1-year high of $3.53.

Affimed (NASDAQ:AFMD – Get Rating) last announced its quarterly earnings results on Thursday, March 23rd. The biopharmaceutical company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.03). Affimed had a negative net margin of 208.85% and a negative return on equity of 52.99%. The firm had revenue of $11.39 million during the quarter, compared to analyst estimates of $7.82 million. Equities analysts anticipate that Affimed will post -0.86 EPS for the current year.

About Affimed

(Get Rating)

Affimed NV engages in the discovery and development of cancer immunotherapies. It is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs.